Holen Sie sich die Stockscreener-App
2.07
0.00%
0.055
Schlusskurs vom Vortag:
$2.015
Offen:
$2.02
24-Stunden-Volumen:
33,206
Relative Volume:
5.75
Marktkapitalisierung:
$5.00M
Einnahmen:
$5.31M
Nettoeinkommen (Verlust:
$-2.90M
KGV:
-1.3935
EPS:
-1.4855
Netto-Cashflow:
$-1.18M
1W Leistung:
-4.05%
1M Leistung:
-9.23%
6M Leistung:
-55.62%
1J Leistung:
-31.46%
1-Tages-Spanne:
$2.00
$2.185
1-Wochen-Bereich:
$2.00
$2.185
52-Wochen-Spanne:
$1.92
$15.60
Bionexus Gene Lab Corp Stock (BGLC) Company Profile
Firmenname
Bionexus Gene Lab Corp
Sektor
Branche
Telefon
1-307-241-6898
Adresse
10-2 TOWER B, VERTICAL BUSINESS SUITE,, KUALA LUMPUR
Compare BGLC vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BGLC
BioNexus Gene Lab Corp Common stock
|
0.343 | 201.51M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.40 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.48 | 432.93M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.13 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.29 | 288.61M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.58 | 0 | 0 | 0 | 0 | 0.00 |
Bionexus Gene Lab Corp Aktie (BGLC) Neueste Nachrichten
BioNexus Gene Lab (BGLC) Extends Decline, Tests Key Support at $1.92Crowd Entry Signals - Newser
BioNexus Gene Lab Corp 1Q 2026: Revenue $22.84K, EPS ($0.23) — 10-Q Summary - TradingView
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] BioNexus Gene Lab Corp Quarterly Earnings Report - Stock Titan
TradingKey - TradingKey
Is BioNexus Lab (BGLC) stock fading in strength |Community Buy Alerts - newser.com
BioNexus Lab (BGLC) Risk Reward Ratio | BioNexus Gene Lab posts strong revenue, net lossCertified Trade Ideas - vinhcong.tayninh.gov.vn
BioNexus Gene Lab: Chemical Raw Materials & Genomic Screening Business Overview, Growth Strategies, and Market Insights 19233034 - Minichart
BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61) - TradingView
[10-K] BioNexus Gene Lab Corp Files Annual Report - Stock Titan
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Analyst Upgrade: Will BioNexus Gene Lab Corp stock recover after earningsPortfolio Profit Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioNexus Gene Lab Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Will BioNexus Lab (BGLC) Stock Grow in 2026 | Price at $2.15, Down 4.41%Public Sentiment - Xã Thanh Hà
Ideas Watch: Does BioNexus Gene Lab Corp stock reflect fundamentalsShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
BGLC Stock Price, Quote & Chart | BIONEXUS GENE LAB CORP (NASDAQ:BGLC) - ChartMill
How is BioNexus Lab (BGLC) Stock performing in 2026 | Price at $2.30, Up 1.71%Diagonal Spread Trade - Newser
Can BioNexus Lab (BGLC) Stock Go Higher | Price at $2.23, Up 0.98%Trade Idea Marketplace - Newser
BGLC SEC FilingsBionexus Gene La 10-K, 10-Q, 8-K Forms - Stock Titan
[NT 10-K] BioNexus Gene Lab Corp SEC Filing - Stock Titan
12 Industrials Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Volume Recap: Can BioNexus Gene Lab Corp be the next market leader2026 Pullback Review & Stock Portfolio Risk Control - baoquankhu1.vn
Portfolio Update: Is BioNexus Gene Lab Corp in a consolidation phase2026 Sector Review & Daily Growth Stock Tips - baoquankhu1.vn
Will BioNexus Gene Lab Corp stock recover after earningsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
Aug Highlights: Does LTRY have declining or rising EPS2026 Intraday Action & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Tech Rally: Will BioNexus Gene Lab Corp outperform its industry peersPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
12 Industrials Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization - Stock Titan
BioNexus Gene Lab appoints commercial officer at Fidelion By Investing.com - Investing.com Nigeria
BioNexus Gene Lab appoints commercial officer at Fidelion - Investing.com India
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform - Bitget
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - The Manila Times
BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics - Quiver Quantitative
Cancer relapse blood tests: Fidelion hires 15-year oncology diagnostics veteran - Stock Titan
12 Industrials Stocks Moving In Monday's Intraday Session - Sahm
Sell Signal: Is BioNexus Gene Lab Corp a strong candidate for buy and holdQuarterly Portfolio Review & Risk Managed Trade Strategies - baoquankhu1.vn
Breakouts Watch: Will BioNexus Gene Lab Corp stock recover after earningsJuly 2025 Levels & Growth Focused Stock Reports - baoquankhu1.vn
BGLC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - Bitget
Chemrex board cut to two as BioNexus weighs new growth options - Stock Titan
BGLCBionexus Gene La Latest Stock News & Market Updates - Stock Titan
Financial Comparison: Beauty Health (NASDAQ:SKIN) vs. BioNexus Gene Lab (NASDAQ:BGLC) - Defense World
BioNexus Gene Lab (NASDAQ:BGLC) Stock Price Up 1.7% – Still a Buy? - Defense World
Sentiment Review: Does T Stamp Inc stock reflect fundamentalsJuly 2025 Sentiment & Smart Allocation Stock Tips - baoquankhu1.vn
Will BioNexus Gene Lab Corp. stock recover after earningsInsider Selling & Smart Swing Trading Alerts - mfd.ru
BGLC Should I Buy - Intellectia AI
Analyst Upgrade: What is the Moat Score of BioNexus Gene Lab CorpJuly 2025 Rallies & Weekly Market Pulse Alerts - baoquankhu1.vn
BioNexus Launches Regional Deployment of VitaGuard MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - Finviz
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market - marketscreener.com
BioNexus Launches Regional Deployment of VitaGuard™ MRD - GlobeNewswire
Finanzdaten der Bionexus Gene Lab Corp-Aktie (BGLC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):